Neuro-Oncology

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2022

Collapse All | Expand All

 

    Society of Neuro-Oncology (SNO)
    27th Annual Scientific Meeting and Education Day in Tampa, Fla. (Nov. 16-20, 2022)
    • Pathogenic germline mutations in glioma patients.

      McDonald MF, Prather LL, Helfer CR, Ludmir EB, Echeverria AE, Patel AJ, et al.

<2021

Collapse All | Expand All

 

    Society of Neuro-Oncology (SNO)
    26th Annual Scientific Meeting and Education Day in Boston, Mass. (Nov. 18-21, 2021)
    • An innovative virtual multi-institutional, multidisciplinary neuro-oncology tumor board: The NIH-NOB experience during the COVID-19 pandemic.

      Rogers J, Acquaye A, Ikiddeh-Barnes U, Benson K, Boris L, Akindona F, et al.

    Society of Neuro-Oncology (SNO)
    25th Virtual Annual Scientific Meeting and Education Day (Nov. 19-21, 2020)
    • IDH mutation status and the development of venous thromboembolism in astrocytoma patients.

      Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Ludmir E, et al.

    American Academy of Neurology (AAN)
    72nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)
    • Treatment strategies for glioblastoma in older patients: Age is just a number.

      Mandel J, Youssef M, Ludmir E, Patel A, Jalali A, Treiber J, et al.

    • Examining the impact of isocitrate dehydrogenase (IDH) gene status on the development of venous thromboembolism in glioma patients.

      Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Wu J, et al.

    Society of Neuro-Oncology (SNO)
    23rd Annual Scientific Meeting and Education Day in New Orleans, La. (Nov. 15-18, 2018)
    • Effect of health disparities on overall survival of patients with glioblastoma.

      Mandel J, Youssef M, Nam J, Patel A, Liu D, Wu J, et al.

    American Society of Clinical Oncology (ASCO)
    54th Annual Meeting in Chicago, Ill. (June 1-5, 2018)
    • Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.

      De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers S-PS, Zhou S, et al.

    American Academy of Neurology (AAN)
    70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)
    American Academy of Neurology (AAN)
    68th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)
    • Impact of IDH-1 mutation status on outcome in clinical trials for recurrent glioblastoma.

      Mandel J, Cachia D, Liu DD, Aldape K, Fuller G, De Groot J

    American Society of Clinical Oncology (ASCO)
    51st Annual Meeting in Chicago, Ill. (May 29 - June 2, 2015)
    American Society of Clinical Oncology (ASCO)
    50th Annual Meeting in Chicago, Ill. (May 30 - June 3, 2014)
    • Adverse effects of bevacizumab in brain tumor patients.

      Pawar T, Ladha H, Mandel J, Gilbert M, O'Brien B, Hamza M, et al.

    • Venous thromboembolism (VTE) and glioblastoma.

      Yust-Katz S, Mandel J, Ying Y, Wu J, Courtney C, Ladha H, et al.

    American Academy of Neurology (AAN)
    66th Annual Meeting in Philadelphia, Penn. (April 26 - May 3, 2014)
    • Improved progression free survival in 1p/19q co-deleted anaplastic oligodendroglioma treated with both chemotherapy and radiation therapy at diagnosis.
      [Platform Presentation]

      Mandel J, Webre CC, Shonka NA, Yung WK, De Groot J

    Society of Neuro-Oncology (SNO)
    18th Annual Meeting in San Francisco, Calif. (Nov. 21-24, 2013)
    • Survival outcomes of patients with recurrent anaplastic glioma treated with bevacizumab.

      Hamza M, O'Brien B, Mandel J, de Groot J

    • Glioblastoma and leptomeningeal dissemination.

      Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M

    European Neurological Society (ENS)
    23rd Annual Meeting in Barcelona, Spain (June 8-11, 2013)
    • Tosedostat and posterior reversible encephalopathy syndrome (PRES).
      [Oral Presentation]

      Mandel J, Tremont-Lukats I, Tummala S

    • Severe neurological disability in cancer patients acutely infected with the West Nile virus (WNV).

      Mandel J, Woodman K, Tummala S, Tremont-Lukats I

    American Society of Clinical Oncology (ASCO)
    49th Annual Meeting in Chicago, Ill. (May 31 - June 4, 2013)
    • Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

      Hamza MA, Mandel J, Conrad CA, Gilbert MR, Yung WKA, Puduvalli VK, et al.

    American Academy of Neurology (AAN)
    64th Annual Meeting in New Orleans, La. (April 21-28, 2012)
    • Sporadic CJD (VV2 Type) presenting with central vestibular abnormalities.

      Mandel J, Oas J

    • Early predictors of progression in idiopathic sensory neuropathy.

      Mandel J, Quick A, Lawson V